175 related articles for article (PubMed ID: 7981137)
21. Erythropoiesis in primary (idiopathic) osteomyelofibrosis: quantification, PCNA-reactivity, and prognostic impact.
Thiele J; Windecker R; Kvasnicka HM; Titius BR; Zankovich R; Fischer R
Am J Hematol; 1994 May; 46(1):36-42. PubMed ID: 7910431
[TBL] [Abstract][Full Text] [Related]
22. Ki-S1 and proliferating cell nuclear antigen expression of bone marrow macrophages. Immunohistochemical and morphometric study including reactive (inflammatory) myelitis, secondary aplastic anemia, AIDS, myelodysplastic syndromes and primary (idiopathic) osteomyelofibrosis.
Titius BR; Thiele J; Schaefer H; Kreipe H; Fischer R
Acta Haematol; 1994; 91(3):144-9. PubMed ID: 7522384
[TBL] [Abstract][Full Text] [Related]
23. The value of bone marrow histology in differentiating between early stage Polycythemia vera and secondary (reactive) Polycythemias.
Thiele J; Kvasnicka HM; Zankovich R; Diehl V
Haematologica; 2001 Apr; 86(4):368-74. PubMed ID: 11325641
[TBL] [Abstract][Full Text] [Related]
24. [Fine structure of megakaryocyte precursor cells (promegakaryoblasts) derived from smears and sections of bone marrow tissue in patients with chronic myeloid leukemia and so-called primary osteomyelofibrosis with accompanying thrombocythemia].
Thiele J; Wagner S; Sander C; Dienemann D; Weuste R; Bertsch HP; Fischer R; Stein H
Verh Dtsch Ges Pathol; 1990; 74():130-4. PubMed ID: 1708570
[TBL] [Abstract][Full Text] [Related]
25. Effects of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) on megakaryocytopoiesis in human bone marrow.
Orazi A; Cooper RJ; Tong J; Gordon MS; Battiato L; Sledge GW; Kaye JA; Kahsai M; Hoffman R
Exp Hematol; 1996 Sep; 24(11):1289-97. PubMed ID: 8862439
[TBL] [Abstract][Full Text] [Related]
26. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies.
Thiele J; Kvasnicka HM; Fuchs N; Brunnbauer K; Volkwein N; Schmitt-Graeff A
Haematologica; 2003 Oct; 88(10):1130-8. PubMed ID: 14555309
[TBL] [Abstract][Full Text] [Related]
27. [Importance of immunomorphometric evaluation of the size and number of megakaryocytes in normal and pathologic bone marrow].
Marisavljević D; Rolović Z; Mitrović D
Srp Arh Celok Lek; 1993; 121(3-7):57-61. PubMed ID: 7716637
[TBL] [Abstract][Full Text] [Related]
28. Histomorphometric study of megakaryocytes in bone marrow in selected myeloproliferative and lymphoproliferative diseases.
Lemancewicz D; Dziecioł J; Kłoczko J; Litwiejko-Pietryńczak E; Bogusłowicz W
Folia Morphol (Warsz); 2003 Feb; 62(1):51-6. PubMed ID: 12769178
[TBL] [Abstract][Full Text] [Related]
29. Histologic criteria for classification and differential diagnosis of chronic myeloproliferative disorders.
Frisch B; Bartl R; Burkhardt R; Jäger K
Haematologia (Budap); 1984; 17(2):209-26. PubMed ID: 6534829
[TBL] [Abstract][Full Text] [Related]
30. Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis.
Chott A; Gisslinger H; Thiele J; Fritz E; Linkesch W; Radaszkiewicz T; Ludwig H
Br J Haematol; 1990 Jan; 74(1):10-6. PubMed ID: 2310690
[TBL] [Abstract][Full Text] [Related]
31. Proliferating cell nuclear antigen expression by erythroid precursors in normal bone marrow, in reactive lesions and in polycythaemia rubra vera.
Thiele J; Meuter RB; Titius RB; Zankovich R; Fischer R
Histopathology; 1993 May; 22(5):429-35. PubMed ID: 8102113
[TBL] [Abstract][Full Text] [Related]
32. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders.
Bock O; Schlué J; Mengel M; Büsche G; Serinsöz E; Kreipe H
J Pathol; 2004 May; 203(1):609-15. PubMed ID: 15095485
[TBL] [Abstract][Full Text] [Related]
33. Analysis of megakaryocyte ploidy in patients with thrombocytosis.
Kanz L; Hollen C; Friese P; Burstein SA
Int J Cell Cloning; 1990 Jul; 8(4):299-306. PubMed ID: 2401806
[TBL] [Abstract][Full Text] [Related]
34. [Megakaryopoiesis in chronic myeloproliferative disorders].
Nagasawa T
Rinsho Ketsueki; 1993 May; 34(5):551-6. PubMed ID: 8315826
[TBL] [Abstract][Full Text] [Related]
35. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
36. Abnormalities of megakaryocytes in myelitis and chronic myeloproliferative diseases.
Thiele J; Holgado S; Choritz H; Georgii A
Virchows Arch B Cell Pathol Incl Mol Pathol; 1982; 41(1-2):67-81. PubMed ID: 6134385
[TBL] [Abstract][Full Text] [Related]
37. Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders - aids to diagnosis and classification.
Thiele J; Kvasnicka HM; Fischer R
Ann Hematol; 1999 Nov; 78(11):495-506. PubMed ID: 10602893
[TBL] [Abstract][Full Text] [Related]
38. Assessment of cell proliferation in normal and pathological bone marrow biopsies: a study using double sequential immunophenotyping on paraffin sections.
Pellegrini W; Facchetti F; Marocolo D; Salvi L; Capucci A; Tironi A; Rossi G
Histopathology; 1995 Nov; 27(5):397-405. PubMed ID: 8575729
[TBL] [Abstract][Full Text] [Related]
39. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
40. von Willebrand factor is the most reliable immunohistochemical marker for megakaryocytes of myelodysplastic syndrome and chronic myeloproliferative disorders.
Chuang SS; Jung YC; Li CY
Am J Clin Pathol; 2000 Apr; 113(4):506-11. PubMed ID: 10761451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
